Brk Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Raf Kinase Inhibitor V | 918505-84-7 | sc-222241 sc-222241A | 1 mg 10 mg | $198.00 $480.00 | 2 | |
Raf Kinase Inhibitor V is a selective inhibitor that disrupts the Raf-MEK-ERK signaling cascade, crucial for cellular proliferation. Its unique binding affinity is attributed to specific hydrogen bonding and hydrophobic interactions with the Raf kinase domain. The compound's structural flexibility allows it to adapt to conformational changes in the target, enhancing its inhibitory potency. Additionally, Raf Kinase Inhibitor V demonstrates distinct reaction kinetics, facilitating effective modulation of downstream signaling pathways. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Vemurafenib is a selective BRAF inhibitor that binds to the active form of BRAF V600E, preventing downstream signaling in the MAPK pathway, inhibiting cell proliferation and tumor growth. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $138.00 $255.00 $273.00 $403.00 $12240.00 | 6 | |
Dabrafenib selectively inhibits BRAF V600E, reducing ERK phosphorylation and blocking tumor cell proliferation in melanoma. | ||||||
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
Encorafenib is a potent BRAF V600E inhibitor that impedes the MAPK pathway, leading to apoptosis in BRAF-mutated cancers. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple kinases, including BRAF, inhibiting tumor angiogenesis and cell growth in various malignancies. | ||||||
RAF265 | 927880-90-8 | sc-364599 | 5 mg | $191.00 | ||
RAF265 is a pan-RAF kinase inhibitor that targets both BRAF and CRAF, inhibiting MAPK pathway signaling in cancer cells. | ||||||
LY3009120 | 1454682-72-4 | sc-507538 | 5 mg | $125.00 | ||
LY3009120 is a potent BRAF inhibitor that disrupts the MAPK pathway, suppressing tumor growth in BRAF-mutated cancers. | ||||||
TAK 632 | 1228591-30-7 | sc-473801 | 5 mg | $224.00 | ||
TAK-632 inhibits BRAF V600E, blocking downstream signaling and demonstrating antitumor activity in BRAF-mutated cancers. | ||||||